How do I buy Kyverna Therapeutics (KYTX) stock?

You can purchase shares of Kyverna Therapeutics (NASDAQ:KYTX) through any online brokerage.View our list of the best stock brokerages

Who are Kyverna Therapeutics (KYTX) competitors?

Other companies in Kyverna Therapeutics’s space includes: Monopar Therapeutics Inc (NASDAQ:MNPR), Replimune Group Inc (NASDAQ:REPL), Prothena Corp PLC (NASDAQ:PRTA), Cullinan Therapeutics Inc (NASDAQ:CGEM) and PureTech Health PLC (NASDAQ:PRTC).

What is the forecast, or price target, for Kyverna Therapeutics (KYTX) stock?

Kyverna Therapeutics has a consensus price target of $21.50.

What is the current price for Kyverna Therapeutics (KYTX)?

The stock price for Kyverna Therapeutics (NASDAQ: KYTX) is $8.74 last updated January 15, 2026 at 5:31 PM EST.

Does Kyverna Therapeutics (KYTX) pay a dividend?

There are no upcoming dividends for Kyverna Therapeutics.

When is Kyverna Therapeutics (NASDAQ:KYTX) reporting earnings?

Kyverna Therapeutics does not have any upcoming earnings scheduled.

Is Kyverna Therapeutics (KYTX) going to split?

There is no upcoming split for Kyverna Therapeutics.

What sector and industry does Kyverna Therapeutics (KYTX) operate in?

Kyverna Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Kyverna Therapeutics (KYTX) Stock Price, Quote, News & History

Bulls vs Bears

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Name

Revenue

Change

Gross

Change

EBITDA

Change

EBIT

Change

Earnings

Change

About

Sector

Health Care

Industry

Biotechnology

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made...

Comments